Posted by Michael Wonder on 16 Jul 2020
European Commission approves third nintedanib indication in pulmonary fibrosis
15 July 2020 - The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases with a progressive phenotype beyond idiopathic pulmonary fibrosis.
Boehringer Ingelheim today announced that the European Commission has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype beyond idiopathic pulmonary fibrosis.
The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.
